Myomo, Inc. (MYO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 8 | 14 | 16 | 19 | 33 | 41 | 43 | 46 |
| Operating profit | $m | -14 | -12 | ||||||
| Net profit | $m | -12 | -10 | -11 | -8 | -6 | -16 | -15 | -13 |
| EPS reported | $ | -0.37 | -0.34 | ||||||
| Operating cashflow per share | $ | -0.35 | -0.17 | ||||||
| Capex per share | $ | 0.04 | 0.04 | ||||||
| FCF per share | $ | -0.39 | -0.21 | ||||||
| Free cash flow | $m | -16 | -9 | ||||||
| Net debt | $m | -7 | -1 | ||||||
| Book value equity | $m | 11 | 6 | ||||||
| Book value per share | $ | 0.27 | 0.14 | ||||||
| Number of shares | m | 41.86 | 42.7 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.34 | 6.53 | ||||||
| P/S LTM | x | 0.93 | 0.88 | ||||||
| P/FCF LTM | x | -2.34 | -4.31 | ||||||
| EV/EBITDA LTM | x | -3.50 | -3.80 | ||||||
| EV/Sales LTM | x | 1.06 | 1.74 | ||||||
| Earnings Yield LTM | % | -40.89% | -19.75% | ||||||
| FCF Yield | % | -42.67% | -23.19% | ||||||
| Quality | |||||||||
| ROE | % | -136.57% | -142.02% | ||||||
| ROIC | % | -46.78% | -45.17% | ||||||
| Operating margin | % | -35.19% | -27.05% | ||||||
| Gross margin | % | +65.70% | +68.35% | ||||||
| FCF/Sales | % | -39.71% | -20.42% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +25.73% | +32.90% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.84 | -0.44 | ||||||
| Net Debt/EBITDA | x | -0.42 | -0.78 | ||||||
| EBIT/Net interest | x | -15.52 | -6.54 | ||||||
| Net debt/market cap | % | +29.46% | +18.03% | ||||||
| Net debt/Equity | x | -0.63 | -0.25 | ||||||
| Gross debt/equity | x | 1.70 | 3.44 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free